ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2360

Prevalence, Management and Outcomes of PET Positive Large Vessel Vasculitis in Difficult to Treat PMR and GCA Patients

Pravin Patil1, Shaifali Jain2, Katerina Achilleos3, Tochukwu Adizie1, Mark Williams1, Matthew Tam2 and Bhaskar Dasgupta4, 1Rheumatology, Southend University Hospital, Westcliff on sea, United Kingdom, 2Radiology, Southend University Hospital, Westcliff on sea, United Kingdom, 3Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, 4Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: giant cell arteritis, polymyalgia rheumatica, positron emission tomography (PET), tocilizumab and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

 Management of PMR and GCA can be challenging in patients with persistently elevated inflammatory markers, prominent constitutional symptoms and inadequate steroid response. We undertook an audit in such difficult to treat cases of the utility of FDG-PET CT scanning and outcomes of therapeutic decisions subsequently made.

Methods:  We report a retrospective case notes review of 52 rheumatology patients with active PMR, GCA despite optimal steroid/ methotrexate therapy or patients with an unexplained systemic illness who had PET-CT from 2008–2012.  FDG uptake was graded on a 4-point scale and grade 2 or more was accepted as positive.

Results: Of the 52, 68 % were female (median age 70, range 57–89), 23 PMR and 20 had GCA (12  biopsy positive). 63 % PMR and GCA patients were on steroids. The average dose of Prednisolone prior to PET scan was 6mg daily in PET positives compared to 21mg daily in PET negative patients.

 Large vessel vasculitis (LVV): 15 had avid FDG uptake in the subclavian, aortic and axillary arteries, suggesting presence of LVV. All had constitutional symptoms notably night sweats, weight loss and lethargy. The average CRP in patients with LVV was 112mg/dl (range 13-403). Where PET scans were negative, the average CRP was 19 (1-48). There was no significant difference in gender, incidence of PMR, GCA, and resistance to treatment in both groups. 8 out of 9 with LVV who had abdominal CT scan were found to have inflammatory aortitis (soft tissue vascular cuffing) on retrospective CT review. All patients with LVV had successful clinical response to escalation of immunosuppression with 4-6 weeks post treatment mean CRP of 7 (1-26). 78% were treated with high dose Predinisolone and Leflunomide (53%). 4 patients required treatment with Tocilizumab (TCZ). 1 patient with retroperitoneal fibrosis and LVV associated with pan aortitis was treated with Rituximab. All patients on TCZ showed reversal of FDG avidity, normalized CRP, reduction of prednisolone to < 90% pre TCZ dose and 1 showed re-vascularisation of axillary artery stenosis on follow up CT angiography and ultrasound. 

Non LVV findings on FDG PET: 2 patients had uptake in sterno-clavicular and sacroiliac joints suggestive of SpA. One patient with connective tissue disease overlap had symmetrical uptake in shoulders consistent with inflammatory arthritis. In 2 patients with atypical clinical presentation the diagnosis of PMR was confirmed with bursal & entheseal uptake in the shoulder/hips. In 3 cases FDG PET revealed cancer (pancreas 2, metastatic breast 1).

Conclusion:  LVV is a common finding in both PMR and GCA exhibiting lack of steroid response, constitutional symptoms and raised inflammatory markers. Abdominal CT scan may provide important diagnostic clues of aortitis which can be confirmed on FDG-PET scan. Scan results are influenced by dose of steroid intake and we suggest prednisolone no higher than 7.5 -10mg daily a week prior to the scan. Patients on higher doses may have false negative scans. FDG PET can also reveal occult malignancies or confirm the PMR diagnosis.  Novel agents like leflunomide and tocilizumab provide targeted and effective therapy in refractory patients with reversal of FDG avidity on and re-vascularisation on repeat scans.


Disclosure:

P. Patil,
None;

S. Jain,
None;

K. Achilleos,
None;

T. Adizie,
None;

M. Williams,
None;

M. Tam,
None;

B. Dasgupta,

Merck Pharmaceuticals,

5.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-management-and-outcomes-of-pet-positive-large-vessel-vasculitis-in-difficult-to-treat-pmr-and-gca-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology